MARKET

RDUS

RDUS

Radius Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.60
-0.31
-1.64%
Opening 13:52 01/24 EST
OPEN
18.95
PREV CLOSE
18.91
HIGH
19.05
LOW
18.31
VOLUME
283.31K
TURNOVER
--
52 WEEK HIGH
29.97
52 WEEK LOW
16.43
MARKET CAP
858.81M
P/E (TTM)
-5.7073
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of RDUS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

RDUS News

  • Moving Average Crossover Alert: Radius Health
  • Zacks.2d ago
  • Radius Health slips 3% on Tymlos outlook
  • Seeking Alpha - Article.01/13 15:31
  • Radius Expects FY20 TYMLOS Sales $220M-$235M, Sees Cash Burn Below $80B
  • Benzinga.01/13 14:06
  • Radius Exceeds 2019 Financial Guidance and Provides Business Update at the 38th Annual J.P. Morgan Healthcare Conference
  • GlobeNewswire.01/13 14:00

More

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-1.76%

Hot Stocks

Name
Price
%Change

About RDUS

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.
More

Webull offers Radius Health Inc (RDUS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.